Mooranian Armin, Negrulj Rebecca, Takechi Ryu, Jamieson Emma, Morahan Grant, Al-Salami Hani
Biotechnology & Drug Development Research Laboratory, School of Pharmacy, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia.
School of Public Health, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia.
Ther Deliv. 2017 Oct;8(10):833-842. doi: 10.4155/tde-2017-0042.
A semisynthetic primary bile acid (PBA) has exerted hypoglycemic effects in Type 1 diabetic animals, which were hypothesized to be due to its anti-inflammatory and cellular glucose-regulatory effects. Thus, the research purpose aimed to examine antidiabetic effects of a PBA, in terms of cellular inflammation and survival and insulin release, in the context of supporting β-cell delivery and Type 1 diabetic treatment.
MATERIALS & METHODS: 10 formulations were prepared, five without PBA (control) and five with PBA (test). Formulations were used to microencapsulate pancreatic β cells and the microcapsules were examined for morphology, cell viability, insulin release and inflammation.
RESULTS & CONCLUSION: PBA improved cell viability, insulin release and reduced inflammation in a formulation-dependent manner, which suggests potential use in cell delivery and diabetes treatment. [Formula: see text].
一种半合成的初级胆汁酸（PBA）在1型糖尿病动物中具有降血糖作用，据推测这是由于其抗炎和细胞葡萄糖调节作用。因此，本研究目的旨在在支持β细胞递送和1型糖尿病治疗的背景下，从细胞炎症、存活和胰岛素释放方面研究一种PBA的抗糖尿病作用。
制备了10种制剂，5种不含PBA（对照），5种含PBA（试验）。用这些制剂对胰腺β细胞进行微囊化，并对微囊进行形态、细胞活力、胰岛素释放和炎症检测。
PBA以制剂依赖的方式提高了细胞活力、胰岛素释放并减轻了炎症，这表明其在细胞递送和糖尿病治疗中具有潜在用途。[公式：见正文]
